Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 2014 Jan;70(1):168-77. doi: 10.1016/j.jaad.2013.09.020. Epub 2013 Nov 1.

From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.

Author information

  • 1Department of Dermatology, St Luke's-Roosevelt Hospital Center, New York, New York.
  • 2Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
  • 3Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey.
  • 4Department of Dermatology, Mount Sinai School of Medicine, New York, New York.
  • 5Oregon Medical Research Center, Portland, Oregon.
  • 6Department of Dermatology, Baylor College of Medicine, Houston, Texas.
  • 7Department of Dermatology, St Luke's-Roosevelt Hospital Center, New York, New York. Electronic address: jmw27@columbia.edu.

Abstract

BACKGROUND:

Many studies have identified cardiovascular risk factors in patients with psoriasis. Some psoriasis therapies may increase cardiovascular disease (CVD) and others may decrease CVD.

OBJECTIVE:

We reviewed the literature to define the impact of common psoriasis therapies on cardiovascular measures and outcomes.

RESULTS:

Phototherapy has no major cardiovascular impact and may reduce levels of proinflammatory cytokines. Acitretin increases serum lipids and triglycerides, but has not been shown to increase cardiovascular risk. Cyclosporine A increases blood pressure, serum triglycerides, and total cholesterol. Methotrexate is associated with a decreased risk of CVD morbidity and mortality. Among the biologics, data for tumor necrosis factor inhibitors suggest an overall reduction in cardiovascular events. Most data on short-term ustekinumab use suggest no effect on major adverse cardiovascular events, however some authorities remain concerned. Nevertheless, ustekinumab use over a 4-year period shows a decrease in major adverse cardiovascular events when compared both with the general US population and with psoriatics in Great Britain.

LIMITATIONS:

Most studies lack the power and randomization of large clinical trials and long-term follow-up periods. In addition, the increased risk of CVD associated with psoriasis itself is a confounding factor.

CONCLUSION:

Some therapies for moderate to severe psoriasis, including methotrexate and tumor necrosis factor inhibitors, may reduce cardiovascular events in psoriatic patients. Ustekinumab appears to be neutral but there may be a long-term benefit. Appropriate patient counseling and selection and clinical follow-up are necessary to maximize safety with these agents. Further long-term study is necessary to quantify the benefits and risks associated with biologic therapies.

Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

KEYWORDS:

CHF; CVD; DM; HTN; IL; MACE; MI; MTX; PUVA; PsA; RA; TNF; TNFi; UV; VEGF; adalimumab; biologic therapies; cardiovascular; cardiovascular disease; congestive heart failure; cyclosporine; diabetes mellitus; etanercept; hypertension; infliximab; interleukin; major adverse cardiovascular events; methotrexate; mycophenolate mofetil; myocardial infarction; psoralen plus ultraviolet A; psoriasis; psoriatic arthritis; rheumatoid arthritis; tumor necrosis factor; tumor necrosis factor inhibitor; ultraviolet; ultraviolet therapy; ustekinumab; vascular endothelial growth factor

PMID:
24184141
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk